129 related articles for article (PubMed ID: 26124331)
21. lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.
Wang L; Bi R; Li L; Zhou K; Yin H
Aging (Albany NY); 2021 Aug; 13(15):19272-19281. PubMed ID: 34374662
[TBL] [Abstract][Full Text] [Related]
22. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
Maehara S; Tanaka S; Shimada M; Shirabe K; Saito Y; Takahashi K; Maehara Y
Int J Cancer; 2004 Nov; 112(2):184-9. PubMed ID: 15352029
[TBL] [Abstract][Full Text] [Related]
23. Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.
Nguyen Ho-Bouldoires TH; Clapéron A; Mergey M; Wendum D; Desbois-Mouthon C; Tahraoui S; Fartoux L; Chettouh H; Merabtene F; Scatton O; Gaestel M; Praz F; Housset C; Fouassier L
Free Radic Biol Med; 2015 Dec; 89():34-46. PubMed ID: 26169728
[TBL] [Abstract][Full Text] [Related]
24. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K
Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
Guo Y; Ziesch A; Hocke S; Kampmann E; Ochs S; De Toni EN; Göke B; Gallmeier E
J Cell Mol Med; 2015 Feb; 19(2):340-50. PubMed ID: 25331547
[TBL] [Abstract][Full Text] [Related]
27. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Li Y; Köpper F; Dobbelstein M
Cancer Lett; 2018 Aug; 428():45-54. PubMed ID: 29704518
[TBL] [Abstract][Full Text] [Related]
29. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
30. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
31. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
[TBL] [Abstract][Full Text] [Related]
32. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
33. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
34. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
35. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
37. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
38. Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells.
Xia QS; Ishigaki Y; Zhao X; Shimasaki T; Nakajima H; Nakagawa H; Takegami T; Chen ZH; Motoo Y
Pancreas; 2011 Jan; 40(1):55-60. PubMed ID: 20871480
[TBL] [Abstract][Full Text] [Related]
39. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.
Lin SP; Lee YT; Wang JY; Miller SA; Chiou SH; Hung MC; Hung SC
PLoS One; 2012; 7(11):e49605. PubMed ID: 23185379
[TBL] [Abstract][Full Text] [Related]
40. Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Drexler R; Wagner KC; Küchler M; Feyerabend B; Kleine M; Oldhafer KJ
J Cancer Res Clin Oncol; 2020 May; 146(5):1125-1137. PubMed ID: 32200459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
